相关实验视频

Updated: Jul 2, 2025

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

在不抑制MS-275的分泌酶活性的情况下降低了氨基酸β的产生

Yachiyo Mitsuishi¹, Masaki Nakano¹, Hirotatsu Kojima²

¹Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga 520-2192, Japan.

ACS chemical neuroscience

|February 28, 2024

概括

作为基因素脱乙酶抑制剂的MS-275,通过模仿ILEI活性,在阿尔茨海默病模型中降低了粉样β (Aβ) 的产生. 这种化合物提供了一种潜在的治疗策略,可以在不抑制分泌酶活性的情况下降低大脑Aβ积累.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

大脑β-粉样蛋白 (Aβ) 是阿尔茨海默氏症病变的核心.
以前针对β-和γ-分泌酶的治疗策略带来了有限的临床益处和不良事件.
类似介质素的上皮转移诱导剂 (ILEI) 减少了Aβ的产生,而不依赖于分泌酶抑制.

研究的目的:

为了研究MS-275的潜力,一个组织激素脱乙酶 (HDAC) 抑制剂,以减少Aβ生产.
为了确定MS-275的Aβ降低作用是否与HDAC抑制有关或模仿ILEI活性.
在阿尔茨海默病小鼠模型中评估慢性MS-275治疗的疗效.

主要方法:

评估了MS-275对Aβ产生的影响.
研究了MS-275的机制,特别是它与HDAC抑制和ILEI类活性的关系.
向阿尔茨海默病小鼠模型进行慢性MS-275治疗.

主要成果:

MS-275通过一种独立于HDAC抑制的ILEI类机制减少了Aβ的产生.
慢性MS-275治疗显著降低了阿尔茨海默病小鼠模型的大脑皮质和海马体中的Aβ沉积.
MS-275在减少大脑Aβ积累方面表现出有效性.

结论:

通过减少大脑Aβ积累,MS-275对阿尔茨海默病具有治疗潜力.
该化合物通过ILEI模拟途径起作用,为分泌酶抑制提供了替代方案.
MS-275是阿尔茨海默病治疗进一步发展的有希望的候选人.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在Aβ的生产过程中,Aβ的产量大脑的粉样蛋白-β.慢性MS-275的治疗方法基因组脱乙酶 (Histone deacetylases) 是一种一种类型为interleukin的表皮细胞转化为介质细胞的转变诱导剂.

更多相关视频

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...